Job creations
As we closed the books on year two of the COVID-19 pandemic, the Life Sciences market set records as the strongest in history.
Eli Lilly is investing $700 million to build a state-of-the-art facility in Boston, as part of plans to advance its RNA-based therapeutics research and development activities.
Eli Lilly and Company announced plans to build a new manufacturing plant in Concord, North Carolina.
Despite the massive financing from venture capitalists that poured into Massachusetts in 2021, Bay State biopharma companies are struggling to find enough talent to fill the number of available jobs.
The Biotechnology Innovation Organization provides a glimpse of economic development in the biosciences ecosystem at the state and regional levels.
The new building is expected to be ready for occupation in the fourth quarter of 2022 and will feature purpose-built laboratory infrastructure, full-service onsite amenities and multi-functional outdoor spaces.
Pardes is funneling the funds into financing the next stage of clinical trials and commercial production of its lead oral antiviral drug, PBI-0451, for the treatment and prevention of SARS-CoV-2 infections.
Amgen said the expansion would bring 150 construction jobs to the area.
Biopharma companies are eying the establishment of new facilities across the globe that will bolster their manufacturing strategies. BioSpace rounds up some of the latest announcements.
Innocoll Biotherapeutics, Genapsys, and Adicet Bio announced today their relocation and expansion plans.
PRESS RELEASES